1. Home
  2. IMUX vs SRL Comparison

IMUX vs SRL Comparison

Compare IMUX & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • SRL
  • Stock Information
  • Founded
  • IMUX 2016
  • SRL 2017
  • Country
  • IMUX United States
  • SRL China
  • Employees
  • IMUX N/A
  • SRL N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • SRL Professional Services
  • Sector
  • IMUX Health Care
  • SRL Consumer Discretionary
  • Exchange
  • IMUX Nasdaq
  • SRL Nasdaq
  • Market Cap
  • IMUX 100.0M
  • SRL 109.8M
  • IPO Year
  • IMUX N/A
  • SRL N/A
  • Fundamental
  • Price
  • IMUX $1.07
  • SRL $8.57
  • Analyst Decision
  • IMUX Strong Buy
  • SRL
  • Analyst Count
  • IMUX 6
  • SRL 0
  • Target Price
  • IMUX $12.67
  • SRL N/A
  • AVG Volume (30 Days)
  • IMUX 885.0K
  • SRL 19.4K
  • Earning Date
  • IMUX 02-20-2025
  • SRL 01-10-2025
  • Dividend Yield
  • IMUX N/A
  • SRL 12.13%
  • EPS Growth
  • IMUX N/A
  • SRL N/A
  • EPS
  • IMUX N/A
  • SRL N/A
  • Revenue
  • IMUX N/A
  • SRL $33,997,735.00
  • Revenue This Year
  • IMUX N/A
  • SRL N/A
  • Revenue Next Year
  • IMUX N/A
  • SRL N/A
  • P/E Ratio
  • IMUX N/A
  • SRL N/A
  • Revenue Growth
  • IMUX N/A
  • SRL N/A
  • 52 Week Low
  • IMUX $0.97
  • SRL $5.74
  • 52 Week High
  • IMUX $2.11
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 45.08
  • SRL 64.75
  • Support Level
  • IMUX $0.99
  • SRL $6.29
  • Resistance Level
  • IMUX $1.09
  • SRL $9.99
  • Average True Range (ATR)
  • IMUX 0.06
  • SRL 0.60
  • MACD
  • IMUX -0.00
  • SRL 0.26
  • Stochastic Oscillator
  • IMUX 39.89
  • SRL 62.53

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: